逸達生物科技股份有限公司
逸達生物科技股份有限公司在美國、中國及歐洲作為生物醫藥公司營運。其穩定注射劑型研發管線包括：FP-001（已完成用於治療晚期前列腺癌的臨床三期）、FP-004（處於臨床前階段，治療鴉片類藥物成癮）、FP-011 與 FP-014（治療乳癌/前列腺癌的長效緩釋劑型）及 FP-016（治療神經系統疾病）。新化學實體研發管線包含：FP-020（治療類肉瘤病與肺纖維化）、FP-025（MMP-12 抑制劑，處於臨床二期，治療氣喘、COPD 及新冠肺炎相關呼吸窘迫）以及 FP-045（ALDH2 活化劑，用於治療范可尼貧血）。公司成立於 2013 年，總部位於台灣台北。
該股 RSI(6) 為 33.5，處於中性區間，短線無明顯超買超賣訊號。股價跌破5日、20日、60日、120日均線。KD 指標中性（K=32.5）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-29 | -64 | 0 | 0 | -64 |
| 09-24 | -20 | 0 | 0 | -20 |
| 09-23 | -11 | 0 | 0 | -11 |
| 09-22 | -29 | 0 | 0 | -29 |
| 09-21 | -26 | 0 | 0 | -26 |
| 09-18 | -78 | 0 | 0 | -78 |
| 09-17 | +24 | 0 | 0 | +24 |
| 09-16 | +28 | 0 | +1 | +28 |
| 09-15 | +10 | 0 | 0 | +10 |
| 09-14 | +29 | 0 | 0 | +29 |
| 09-11 | -39 | 0 | 0 | -39 |
| 09-10 | -28 | 0 | 0 | -28 |
| 09-09 | -24 | 0 | +1 | -25 |
| 09-08 | -10 | 0 | +1 | -9 |
| 09-07 | +81 | 0 | +3 | +81 |
| 09-04 | -50 | 0 | 0 | -50 |
| 09-03 | -13 | 0 | 0 | -13 |
| 09-02 | +16 | 0 | 0 | +16 |
| 09-01 | -23 | 0 | 0 | -23 |
| 08-31 | +3 | 0 | +1 | +3 |
| 08-28 | +15 | 0 | 0 | +15 |
| 08-27 | +8 | 0 | 0 | +8 |
| 08-26 | +10 | 0 | 0 | +10 |
| 08-25 | -8 | 0 | 0 | -8 |
| 08-24 | +1 | 0 | 0 | +1 |
| 08-21 | +42 | 0 | 0 | +42 |
| 08-20 | +35 | 0 | 0 | +35 |
| 08-19 | -4 | 0 | 0 | -4 |
| 08-18 | -8 | 0 | 0 | -8 |
| 08-17 | -52 | 0 | 0 | -52 |
| 08-14 | -84 | 0 | 0 | -84 |
| 08-13 | +26 | 0 | 0 | +26 |
| 08-12 | -2 | 0 | 0 | -2 |
| 08-11 | -7 | 0 | 0 | -7 |
| 08-10 | 0 | 0 | 0 | 0 |
| 08-07 | +6 | 0 | 0 | +6 |
| 08-06 | -9 | 0 | 0 | -9 |
| 08-05 | 0 | 0 | 0 | 0 |
| 08-04 | -24 | 0 | 0 | -24 |
| 08-03 | -30 | 0 | 0 | -30 |
| 07-31 | -54 | 0 | 0 | -54 |
| 07-30 | -23 | 0 | 0 | -23 |
| 07-29 | +3 | 0 | 0 | +2 |
| 07-28 | -6 | 0 | 0 | -8 |
| 07-27 | +9 | 0 | 0 | +9 |
| 07-24 | -8 | 0 | 0 | -8 |
| 07-23 | +5 | 0 | 0 | +5 |
| 07-22 | +51 | 0 | 0 | +51 |
| 07-21 | +76 | 0 | 0 | +76 |
| 07-20 | +9 | 0 | 0 | +9 |
| 07-17 | -37 | 0 | 0 | -40 |
| 07-16 | -17 | 0 | 0 | -21 |
| 07-15 | +31 | 0 | 0 | +31 |
| 07-14 | -40 | 0 | 0 | -45 |
| 07-13 | -49 | 0 | 0 | -49 |
| 07-09 | -37 | 0 | 0 | -37 |
| 07-08 | -38 | 0 | 0 | -38 |
| 07-07 | +72 | 0 | 0 | +71 |
| 07-06 | +6 | 0 | 0 | +4 |
| 07-03 | +142 | 0 | 0 | +142 |
| 07-02 | +31 | 0 | 0 | +31 |
| 07-01 | 0 | 0 | 0 | -4 |
| 06-30 | -50 | 0 | 0 | -50 |
| 06-29 | +110 | 0 | +4 | +110 |
| 06-26 | -10 | 0 | 0 | -10 |
| 06-25 | -4 | 0 | 0 | -4 |
| 06-24 | +15 | 0 | 0 | +15 |
| 06-23 | +50 | 0 | +3 | +51 |
| 06-22 | -22 | 0 | +1 | -21 |
| 06-18 | -63 | 0 | +21 | -44 |
| 06-17 | -12 | 0 | 0 | -12 |
| 06-16 | -18 | 0 | 0 | -18 |
| 06-15 | -17 | 0 | 0 | -17 |
| 06-12 | +31 | 0 | 0 | +31 |
| 06-11 | -17 | 0 | 0 | -17 |
| 06-10 | +100 | 0 | 0 | +100 |
| 06-09 | -22 | 0 | 0 | -22 |
| 06-08 | +31 | 0 | 0 | +31 |
| 06-05 | +33 | 0 | 0 | +33 |
| 06-04 | +17 | 0 | 0 | +15 |
| 06-03 | +36 | 0 | 0 | +36 |
| 06-02 | -1 | 0 | 0 | -1 |
| 06-01 | +31 | 0 | 0 | +31 |
| 05-29 | -22 | 0 | 0 | -22 |